David Chang
2018
In 2018, David Chang earned a total compensation of $12.8M as President and Chief Executive Officer at Allogene Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $217,641 |
|---|---|
| Option Awards | $3,070,331 |
| Salary | $362,413 |
| Stock Awards | $8,948,152 |
| Other | $250,000 |
| Total | $12,848,537 |
Chang received $8.9M in stock awards, accounting for 70% of the total pay in 2018.
Chang also received $217.6K in non-equity incentive plan, $3.1M in option awards, $362.4K in salary and $250K in other compensation.
Rankings
In 2018, David Chang's compensation ranked 452nd out of 14,244 executives tracked by ExecPay. In other words, Chang earned more than 96.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 452 out of 14,244 | 97th |
Division Manufacturing | 158 out of 5,765 | 97th |
Major group Chemicals And Allied Products | 45 out of 2,128 | 98th |
Industry group Drugs | 36 out of 1,817 | 98th |
Industry Biological Products, Except Diagnostic Substances | 11 out of 339 | 97th |
Source: SEC filing on April 24, 2019.
Chang's colleagues
We found three more compensation records of executives who worked with David Chang at Allogene Therapeutics in 2018.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Allogene Therapeutics CEO David Chang receives $13M in 2018
April 24, 2019